Background although hypertension (HtN) is a predictor of mortality, recent data have questioned the link between baseline HtN and mortality in incident hemodialysis (HD) patients. We used taiwan's National Health Insurance claim data (NHRI-NHIRD-99182) to investigate the association.
Methods
In 1999, this longitudinal cohort study enrolled 5752 new HD patients. Follow-up began from the initiation of HD until death, the end of HD, or the end of 2008. a Kaplan-Meier survival analysis was done. Cox proportional hazard analysis was used to identify the risk factors for mortality. results the prevalence of baseline HtN was 75.47%. Patients with HtN had a higher prevalence of diabetic mellitus (DM) and cardiovascular diseases. the 1-, 5-, and 9-year cumulative survival rates were 95.5, 63.7 and 41.8% in patients with HtN, and 95.5, 71.0, and 52.0% in those without HtN (log-rank test: P <0.001). Multivariate analysis showed that patients with baseline HtN may have a higher survival rate (hazard ratio (HR) 0.901, 95% confidence interval (CI): 0.819-0.992). after stratification by age and DM, only elderly (≥65) patients without DM had a significantly higher survival rate (HR 0.769, 95% CI: 0.637-0.927). HtN predicts lower mortality with increasing age in patients with congestive heart failure (CHF) or coronary artery disease (CaD).
conclusIons there is a reverse (counterintuitive) association between baseline HtN and mortality in elderly HD patients without DM and a clear tendency for a reverse association with increasing age in patients with CHF or CaD. Further study of the association between HtN and mortality in older HD patients may be warranted.
are still inconclusive, 14 especially epidemiological data for national cohort studies of incident HD patients. To explore this hypothesis, we used the Taiwan National Health Insurance (NHI) database to investigate the association between baseline HTN and mortality in HD patients.
Methods database
NHI program has provided compulsory universal health insurance in Taiwan since 1995. With the exception of prison inmates, all citizens are enrolled in the program. All contracted medical institutions must submit standard computerized claim documents for medical expenses. Patients with ESRD are eligible for any type of renal replacement therapy free of any charge; all chronic dialysis patients are covered by NHI.
Data were obtained from the National Health Insurance Research Database 15 and released for research by the Taiwan National Health Research Institute. The National Health Insurance Research Database covers nearly all (99%) inpatient and outpatient medical benefit claims for Taiwan's 23 million residents, is one of the largest and most comprehensive databases in the world, and has been used extensively in various studies. 15 Patient identification numbers, gender, birthday, dates of admission, and discharge, medical institutions providing the services, the ICD-9-CM (International Classification of Diseases, 9th Revision, Clinical Modification) diagnostic and procedure codes (up to five each), and outcomes are encrypted. The dataset was released with de-identified secondary data for public research purposes. All types of personal identification on files connected with the present study were scrambled using surrogate identification numbers to secure patient privacy. The present study was exempted from ethical review. The Bureau of National Health Insurance approves the application (NHRI-NHIRD-99182) after reviewing all the required medical documents. We used the National Health Insurance Research Database for ambulatory care claims, all inpatient claims, and the updated registry for beneficiaries from 1998 to 2008 for this study. All datasets can be interlinked through each individual's unique personal identification number.
Patient selection and definition
We designed a longitudinal cohort study and selected all adult ESRD patients (≥18 years old) on maintenance dialysis who began renal replacement therapy between 1 January 1999, and 31 December 1999 (n = 6,170). ESRD patients on maintenance dialysis were defined as having undergone dialysis for more than 90 days. Patients who had undergone renal transplantation before beginning dialysis were excluded (n = 36). Patients were followed-up from the first reported date of HD to the date of death, a switch to peritoneal dialysis, renal transplantation, or 31 December 2008. Data on patients were censored if they switched to peritoneal dialysis, underwent renal transplantation, or 31 December 2008. The primary outcome (event) was death from any cause. The predictor was HTN. The determination of modality switches after the initial modality choice followed the "60-day rule" used by the USRDS (i.e., any change in modality lasting less than 60 days is not recorded as a "switch" in the database). 16 A total of 5,752 HD patients were analyzed in this study.
ascertaining the demographic and comorbid variables
We linked to the diagnostic codes through the inpatient and outpatient claims databases of the NHI. Our research included not only survival status, but also date of death, patient demographics, and baseline comorbidities. Baseline comorbidities-such as HTN, DM, congestive heart failure (CHF), CAD, cerebrovascular accident, peripheral vascular disease, chronic lung disease, chronic liver disease, and cancer-were important factors affecting mortality and were assessed at the start of dialysis. These characteristics are consistent with those in previous studies and demonstrate the need to adjust when comparing mortality rates among dialysis patients. The ICD-9-CM codes used to define each condition are shown in Appendix 1. An individual was classified as an HTN patient if he or she had essential HTN, secondary HTN, hypertensive heart disease, hypertensive renal disease, or hypertensive retinopathy. An individual was classified as a DM patient if he or she had type 1 DM, type 2 DM, DM without mention of complication, or DM with mention of complications (ketoacidosis, hyperosmolarity, coma, nephropathy, neuropathy, peripheral circulatory disorders, hypoglycemia, retinopathy, and cataract). An individual was classified as a CAD patient if he or she had acute myocardial infarction, old myocardial infarction, angina pectoris or another acute, subacute, or chronic form of ischemic heart disease. An individual was classified as a CHF patient if he or she had left heart failure, right heart failure, systolic heat failure, diastolic heart failure, rheumatic heart failure, acute myocarditis, cardiomyopathy, hypertensive heart failure, or any other form of heart failure. An individual was classified as a peripheral vascular disease patient if he or she had atherosclerosis, aortic aneurysm and dissection, other aneurysms, arterial embolism and thrombosis, phlebitis and thrombophlebitis, portal vein thrombosis, or other peripheral vascular disease. Comorbidities, which the patients had, were determined by whether they fit one of the following two definitions: (i) diagnostic codes from outpatient visits if the patient had an initial diagnosis at any time in the 1 year before the start of dialysis and then had one or more additional diagnoses within the subsequent 12 months. The first and last outpatient visit within 1 year had to have been >30 days apart to avoid accidental inclusion of miscoded patients; (ii) diagnostic codes in hospitalization databases at least once in the 1 year before the start of dialysis.
statistical analyses
The data were analyzed using the Statistical Package for Social Sciences for Windows 17.0 (SPSS, Chicago, IL). Baseline characteristics of groups of patients with and without HTN were compared using Pearson χ 2 tests. Age was entered as a categorical variable (18-44, 45-64, and 65 years or older). Significance was set at P < 0.05. Overall patient survival was described using the Kaplan-Meier method based on dialysis modality. Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived august 2012 | VOLuME 25 NuMBER 8 | AMERICAN JOURNAL OF HYPERTENSION from Cox proportional hazards models. Cox models met the assumption of proportionality of risks. To adjust for potential confounding in the association between comorbidities and the risk of mortality, multivariate analyses were used to model allcause mortality. To test the hypothesis that being in different age groups and having DM have a different effect on mortality in HD patients with and without HTN, we further stratified these HD patients by age-group and DM.
results demographics and clinical characteristics
Of 5,752 HD patients, 4,341 patients (75.47%) had baseline HTN. There were no significant differences between male and female patients. With increasing age, the proportion of HTN increased. Patients with baseline HTN tended to have more comorbidities than those without baseline HTN ( Table 1) .
cumulative survival rate
During the follow-up period, 2,775 patients died (Figure 1) . The mean follow-up time alive on dialysis was 87.13 months (95% CI: 84.94-89.32) in patients without HTN and 80.45 months (95% CI: 79.18-81.72) for patients with HTN. The cumulative survival rate for patients without HTN was 95.5% at 1 year, 71.0% at 5 years, and 52.0% at 9 years, and for patients with HTN was 95.5% at 1 year, 63.7% at 5 years, and 41.8% at 9 years. The log-rank test showed a sig- nificant difference in survival rates between the two groups (log-rank: P < 0.001). Although crude survival was better in patients without HTN, there was a reverse outcome in longterm mortality between the two groups after adjusting for age, gender, and comorbidities (HR: 0.901, 95% CI: 0.819-0.992) ( Table 2) .
risk factors for all-cause mortality in hd patients
A multivariate Cox proportional hazards analysis of baseline data showed that male gender, being ≥45 years old, DM, CHF, CAD, cerebrovascular accident, peripheral vascular disease, chronic lung disease, chronic liver disease, and cancer were associated with a significantly higher mortality rate ( Table 2) . However, the mortality rate for patients with baseline HTN was lower than for those without HTN.
risk factors for all-cause mortality in hd patients stratified by dM and different age groups
We further stratified patients by DM and different age groups ( Table 3) . After multivariate analysis, baseline HTN was an independent predictor for lower mortality only in nonDM HD patients ≥ 65 years old (HR: 0.769, 95% CI: 0.637-0.927). Mortality was higher for male than female patients only in the nonDM group. A history of CHF was a significant predictor of mortality in the DM group and the elderly (≥65 years old).
risk factors for all-cause mortality in hd patients stratified by chF and different age groups
We further stratified patients by CHF and different age groups ( Table 4) . After a multivariate analysis, baseline HTN was an independent predictor for lower mortality in elderly patients both with (HR: 0. DM, diabetic mellitus; n, the number of patients in each subgroup. a The analyses were adjusted for gender, hypertension, congestive heart failure, coronary artery disease, cerebrovascular disease, peripheral vascular disease, chronic lung disease and cancer. All data are hazard ratio (95% confidence interval). *P < 0.05. CHF, congestive heart failure; n, the number of patients in each subgroup. a The analyses were adjusted for gender, hypertension, congestive heart failure, coronary artery disease, cerebrovascular disease, peripheral vascular disease, chronic lung disease and cancer. All data are hazard ratio (95% confidence interval). *P < 0.05.
and cardiovascular diseases, including CHF, CAD, cerebrovascular accident, and peripheral vascular disease. We found a tendency of reverse epidemiology between baseline HTN and subsequent lower mortality; however, it was significant in HD patients ≥65 years old without DM. There was a clear tendency for a reverse association with increasing age in patients with CHF or CAD. We, like Kimura et al., 17 found that baseline normal BP was associated with poor outcomes in nonDM HD patients ≥65 years old. Kimura et al. also reported that HTN had no significant effect on elderly patients. Elderly dialysis patients have a much higher mortality rate. 13 In the presence of strong factors other than BP that affect mortality, the effect of HTN might neither be discovered nor be as important. We also found there was a clear tendency for a reverse association with increasing age in patients with CHF or CAD. It is also possible that a higher BP could be "protective" in the elderly, especially with CHF or CAD, by improving cardiac perfusion or overcoming the resistance of stiff arteries. 9 In addition, the normal-to-low BP may be a marker of the already poor survival rate of elderly dialysis patients, 18, 19 especially with CHF or CAD. Older patients with no HTN might have latent heart failure and thus be more likely to die. 17 The association of normal-to-low BP with mortality was a marker for having had cardiac failure before death. 6, 19 A recent study 20 also showed that the association between low BP and death was especially evident in the short term. To evaluate the hypothesis that elderly dialysis patients without DM, but with one or more other serious conditions, have a poor survival rate, we analyzed mortality, but excluded death in the initial stage, during follow-up. Patients who died in the initial stage (within 90 days after initiation of HD) were excluded from our study; the HR was 0.769 (95% CI: 0.637-0.927) ( Table 3) . We performed an additional analysis of mortality excluding death within 1 year after the initiation of HD. A multivariate analysis showed that baseline HTN was also an independent predictor for lower mortality only in nonDM HD patients ≥65 years old (HR: 0.784, 95% CI: 0.642-0.956). The HR increased from 0.769 to 0.784, which indicated that serious health conditions may be partially responsible for mortality in elderly patients; other reasons for mortality are yet to be determined. Thus, the reason for an inverse association between baseline HTN and mortality may be that a higher BP "protective" in the elderly; in contrast, normal-to-low BP may reflect the fact that organ failure or other events leading to hypotension had occurred before death.
Some reports 7 refer to the tendency of an inverse association between baseline HTN and subsequent mortality in dialysis patients as "reverse epidemiology", a term first used in 1999 by Josef Coresh (cited in Levin et al. 2007) 12 . However, the term appears to have generated confusion and inaccurate usages over the past decade. Levin et al. 12 clarified that the epidemiology is not reversed. Most ESRD dialysis patients have subclinical manifestations of the disease process and often they and their physicians are unaware, until very late in the course of the disease, of how their disease and treatment are affecting them. There appears to be a counterintuitive association between baseline BP and subsequent mortality partly because of unmeasured baseline disease manifestations of risk factors and partly because of the methods used to analyze disease progression and treatment efficacy 7 ; there may be other reasons. There are several limitations to this study. First, although we stratified our patients by age and DM status, like other studies that have used administrative data, we did not control for some unmeasured confounding variables: antihypertensive treatment, BP levels in hypertensive patients, etc. Whether this is based on latent confounding or whether there is a biological basis remains to be determined. Second, the comorbidities relied on the claim data and ICD-9-CM diagnosis codes, but it is possible that some of the diseases were misclassified. Third, we were unable to take into account the severity of the diseases, which reduced our chances of showing the severityrelated effects of comorbidities. Fourth, our study lacked specific data on dialysis adequacy, patient compliance, nutritional status, biochemical data, and socioeconomic characteristics. Finally, it would be better to describe the causes of death and analyze the mortalities of cardiovascular and noncardiovascular diseases; however, the Taiwan Bureau of National Health Insurance does not afford the cross-link information between this and the database with "causes of death".
In conclusion, maintenance of HD patients have a high prevalence of HTN. Using the Taiwan NHI claim data, we found a counterintuitive reverse association between baseline HTN and mortality in nonDM chronic HD patients ≥65 years old. There was a clear tendency for a reverse association with increasing age in patients with CHF or CAD. Additional studies of this counterintuitive reverse association between HTN and mortality in elderly HD patients may be warranted.
